Pam Bondi diagnosed with thyroid cancer

Thyroid cancer continues to be overdiagnosed, Cedars-Sinai study finds

A study led by Cedars-Sinai investigators provides evidence that thyroid cancer continues to be overdiagnosed and that aggressive screening and treatment of thyroid cancer has not led to higher survival rates.

February 07, 2025

Vol.51 No.05

Drugs & Targets

FDA approves Retevmo for medullary thyroid cancer with RET mutation

FDA granted traditional approval to Retevmo (selpercatinib) for adult and pediatric patients two years of age and older with advanced or metastatic medullary thyroid cancer with a RET mutation, as detected by an FDA-approved test, who require systemic therapy.

October 04, 2024

Vol.50 No.37

Drugs & Targets

FDA grants accelerated approval to selpercatinib for pediatric RET-altered metastatic thyroid cancer or solid tumors

FDA granted accelerated approval to selpercatinib (Retevmo, Eli Lilly and Company) for pediatric patients two years of age and older

May 31, 2024

Vol.50 No.22

Clinical Roundup

PFAS forever chemicals could be a risk factor in thyroid cancer, Mount Sinai researchers find

Mount Sinai researchers have discovered a link between certain per- and polyfluoroalkyl substances and an increased risk for thyroid cancer, according to a study published in eBioMedicine.

October 27, 2023

Vol.49 No.40

Drugs & Targets

EC approves Cabometyx as a second-line treatment for radioactive iodine-refractory differentiated thyroid cancer

The European Commission has approved the use of Cabometyx (cabozantinib) as a monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma, refractory or not eligible to radioactive iodine who have progressed during or after prior systemic therapy.

May 06, 2022

Vol.48 No.18

Drugs & Targets

EU CHMP adopts positive opinion for Cabometyx in radioactive iodine-refractory differentiated thyroid cancer

The Committee for Medicinal Products for Human Use of the European Medicines Agency recommended approval of Cabometyx (cabozantinib) as a monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma, refractory or not eligible to radioactive iodine, who have progressed during or after prior systemic therapy.

April 01, 2022

Vol.48 No.13

Pam Bondi diagnosed with thyroid cancer

YOU MAY BE INTERESTED IN

Thyroid cancer continues to be overdiagnosed, Cedars-Sinai study finds

FDA approves Retevmo for medullary thyroid cancer with RET mutation

FDA grants accelerated approval to selpercatinib for pediatric RET-altered metastatic thyroid cancer or solid tumors

PFAS forever chemicals could be a risk factor in thyroid cancer, Mount Sinai researchers find

EC approves Cabometyx as a second-line treatment for radioactive iodine-refractory differentiated thyroid cancer

EU CHMP adopts positive opinion for Cabometyx in radioactive iodine-refractory differentiated thyroid cancer

Renew today!

Subscriber content

Never miss an issue!

Login